REPLIGEN CORP Other Comprehensive Income (Loss), Net of Tax
REPLIGEN CORP (RGEN) reported Other Comprehensive Income (Loss), Net of Tax of $50.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-02-26
- REPLIGEN CORP other comprehensive income (loss), net of tax for the quarter ending 2016-03-31 was $1.90M.
- REPLIGEN CORP other comprehensive income (loss), net of tax for fiscal 2025 was $50.00M.
- REPLIGEN CORP other comprehensive income (loss), net of tax for fiscal 2024 was -$14.72M.
- REPLIGEN CORP other comprehensive income (loss), net of tax for fiscal 2023 was -$3.41M.
- REPLIGEN CORP other comprehensive income (loss), net of tax for fiscal 2015 was -$2.79M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|
| 2025-12-31 | $50.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$14.72M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$3.41M 10-K · filed 2026-02-26 | |
| 2016-03-31 | $1.90M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$2.79M 10-K · filed 2016-02-25 | |
| 2014-12-31 | -$7.77M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |